FUROSEMIDE TABLET

Страна: Канада

Език: английски

Източник: Health Canada

Активна съставка:

FUROSEMIDE

Предлага се от:

SANIS HEALTH INC

АТС код:

C03CA01

INN (Международно Name):

FUROSEMIDE

дозиране:

80MG

Лекарствена форма:

TABLET

Композиция:

FUROSEMIDE 80MG

Начин на приложение:

ORAL

Броя в опаковка:

100/1000

Вид предписание :

Prescription

Терапевтична област:

LOOP DIURETICS

Каталог на резюме:

Active ingredient group (AIG) number: 0101944004; AHFS:

Статус Оторизация:

APPROVED

Дата Оторизация:

2015-02-18

Данни за продукта

1
PRODUCT MONOGRAPH
PR
FUROSEMIDE
FUROSEMIDE TABLETS
USP
20 MG, 40 MG AND 80 MG
DIURETIC
ATC Code: C03CA01
Sanis Health Inc.
1 President’s Choice Circle
Brampton, Ontario
L6Y 5S5
Submission Control No.: 250024
Date of Revision:
April 13, 2021
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
5
ADVERSE REACTIONS
...................................................................................................
9
DRUG INTERACTIONS
.................................................................................................
12
DOSAGE AND ADMINISTRATION
.............................................................................
16
OVERDOSAGE
...............................................................................................................
17
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 18
STORAGE AND STABILITY
.........................................................................................
20
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 20
PART II: SCIENTIFIC INFORMATION
...............................................................................
21
PHARMACEUTICAL INFORMATION
.........................................................................
21
CLINICAL TRIALS
.........................................................................................................
21
DETAILED PHARMACOLOGY
....................................................................................
21
TOXICOLOGY
........